PURPOSE: Standard therapies for localized inoperable @entity1419 ( @entity1419 ) are ineffective. Advances in radiotherapy (RT) techniques and image guidance have enabled ablative doses to be delivered to large @entity96 . This study evaluated the effects of RT dose escalation in the treatment of @entity1419 . @entity1 AND METHODS: Seventy-nine consecutive @entity1 with inoperable @entity1419 were identified and treated with definitive RT from 2002 to 2014. At diagnosis, the median @entity5 size was 7.9 cm (range, 2.2 to 17 cm). Seventy @entity1 (89%) received systemic chemotherapy before RT. RT doses were 35 to 100 Gy (median, 58.05 Gy) in three to 30 fractions for a median @entity6110 ( @entity6110 ) of 80.5 Gy (range, 43.75 to 180 Gy). RESULTS: Median follow-up time for @entity1 alive at time of analysis was 33 months (range, 11 to 93 months). Median @entity1349 ( @entity1349 ) time after diagnosis was 30 months; 3-year @entity1349 rate was 44%. Radiation dose was the single most important prognostic factor; higher doses correlated with an improved local control (LC) rate and @entity1349 . The 3-year @entity1349 rate for @entity1 receiving @entity6110 greater than 80.5 Gy was 73% versus 38% for those receiving lower doses (P = .017); 3-year LC rate was significantly higher (78%) after a @entity6110 greater than 80.5 Gy than after lower doses (45%, P = .04). @entity6110 as a continuous variable significantly affected LC (P = .009) and @entity1349 (P = .004). There were no significant treatment-related @entity137 . CONCLUSION: Delivery of higher doses of RT improves LC and @entity1349 in inoperable @entity1419 . A @entity6110 greater than 80.5 Gy seems to be an ablative dose of RT for large IHCCs, with long-term survival rates that compare favorably with resection.

Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in @entity1 With Inoperable XXXX : A Retrospective Dose Response Analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity6110 :: ('MESH:D017029', 'Disease') :: ['BED', 'biologic equivalent dose'] @entity1419 :: ('MESH:C535533', 'Disease') :: ['IHCC', 'intrahepatic cholangiocarcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1419 :: (MESH:C535533,Disease) :: ['Intrahepatic Cholangiocarcinoma']
